Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2024
Reporting Period: Event-based (Entry into Material Definitive Agreement)
The Company, an emerging growth company incorporated in Nevada, entered into securities purchase agreements on September 12, 2024, for a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Aggregate Gross Proceeds | Approximately $13,000,000 |
| Shares Issued | 2,341,260 shares of Common Stock |
| Warrants Issued | 2,341,260 Warrants (1:1 ratio) |
| Purchase Price (Investors) | $5.50 per share + Warrant |
| Purchase Price (Insiders) | $6.50 per share + Warrant |
| Warrant Exercise Price | $6.40 per share |
| Warrant Initial Exercise Date | March 16, 2025 |
| Warrant Termination Date | March 16, 2030 |
| Placement Agent Fees | 7.0% of gross proceeds from Investors; 3.5% from Insiders |
| Expense Reimbursements | Up to $50,000 (legal) and $25,000 (non-accountable) |
Note: This filing does not provide revenue, profit, cash flow, or debt metrics for the Company's operations.
Material Changes and Transaction Structure
- Capital Raise: The Company secured approximately $13 million in gross proceeds through a registered direct offering.
- Investor Composition: Purchasers include external investors and Company insiders (directors, officers, and employees).
- Pricing Differential: Insiders paid a higher purchase price ($6.50) compared to external investors ($5.50).
- Acceleration Provisions: Warrants may be accelerated if the Company announces positive top-line data (EMACC p-value ≤ 0.05) for its Phase 2 Alzheimer's program (XPro1595) and the stock price exceeds 200% of the exercise price ($12.80) for 15 consecutive trading days within 1.5 years of the announcement, subject to volume requirements.
Outlook, Risks, and Management Commentary
- Closing Date: The Offering is expected to close on or about September 16, 2024, subject to customary conditions.
- Regulatory Status: Securities are issued pursuant to a Prospectus Supplement filed under Form S-3 (Registration No. 333-279036), declared effective on August 7, 2024.
- Legal Opinion: Counsel (Sichenzia Ross Ference Carmel LLP) has issued an opinion regarding the validity of the securities.
- Blackout Periods: Insiders holding warrants may have an additional 60 days to exercise if the termination date falls during a trading blackout period.
Key Facts for Investor Verification
- Verify the final closing date and net proceeds after deducting placement agent fees and expenses.
- Confirm the dilution impact of 2,341,260 new shares and the potential future dilution from 2,341,260 warrants.
- Monitor the Phase 2 Alzheimer's program (XPro1595) for the "positive top line data" trigger that could accelerate warrant exercise.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific adjustment mechanisms and redemption rights.
- Check subsequent filings for the actual cash balance impact post-closing.